Consequences and management of pain in herpes zoster

Journal of Infectious Diseases

Volumn 186, Issue SUPPL. 1, 2002, Pages

  Johnson, Robert W ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; CHICKENPOX VACCINE; FAMCICLOVIR; GABAPENTIN; METHADONE; NORTRIPTYLINE; OXYCODONE; PREDNISONE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR;

ACUTE PHASE RESPONSE; BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COGNITIVE THERAPY; CONFERENCE PAPER; CORDOTOMY; DORSAL RHIZOTOMY; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH EDUCATION; HERPES ZOSTER; HUMAN; INCIDENCE; NERVE BLOCK; NEUROPATHY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SOCIAL SUPPORT; SPINAL CORD STIMULATION; SYMPATHECTOMY; SYMPATHETIC BLOCKING; THALAMOTOMY; VARICELLA ZOSTER VIRUS;

EID: 0037108637     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342970     Document Type: Conference Paper

References (64)

1. DeMoragas JM, Kieland RR. The outcome of patients with herpes zoster. Am Med Assoc Arch Dermatol 1957;75:193-6.
2. Ragozzino MW, Melton LJ, Kurland LT. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-6.
3. Rogers RS III, Tindall, JP. Geriatric herpes zoster. J Am Geriatr Soc 1971;19:495-504.
4. Wood MJ, Kay R. Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7.
5. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
6. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:89-96.
7. Dworkin RH, Portenoy K. Pain and its persistence in herpes zoster. Pain 1996;67:241-51.
8. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:2-20.
9. Donahue JG, Choo PW, Manson JE. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
10. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000;321:794-6.
11. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-9.
12. Bowsher D. Pathophysiology of postherpetic neuralgia: towards a rational treatment. Neurology 1995;45(Suppl 8):S56-7.
13. Johnson MJ, Mehta A, Johnson RW. A proposed zoster international data standard (ZIDS). Presented at the 2d European Federation of IASP Chapters conference (Barcelona), 1997.
14. Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001;20:2429-39.
15. Wutzler P, Doerr HW, von Essen J. Epidemiology of herpes zoster. Biotest Bull 1997;5:301-6.
16. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999;3:335-42.
17. Bhala BB, Ramamoorthy C, Bowsher D, Yelnoorker KN. Shingles and postherpetic neuralgia. Clin J Pain 1988;4:4169-74.
18. Bowsher D. Sensory change in postherpetic neuralgia. In: Watson CPN, ed. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier, 1993:97-107.
19. Henry T. Herpes zoster: a comparative study of general practitioner and patient experience. Curr Med Res Opin 1994;13:207-13.
20. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol 1986;20:651-4.
21. Satterthwaite JR. Postherpetic neuralgia. In: Tollinson CD, ed. Handbook of chronic pain management. Baltimore: Williams & Wilkins, 1989:460-74.
22. Rowbotham MC, Fields HL. Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain 1989;39:129-44.
23. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995;171:701-4.
24. Mauskopf J, Austin R, Dix L, Berzon R. The Nottingham Health Profile as a measure of quality of life in zoster patients: convergent and discriminant validity. Qual Life Res 1994;3:431-5.
25. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: A self-limited disease with severe impact. Neurology 1995;45(Suppl 8):S52-3.
26. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-35.
27. Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for postherpetic neuralgia in the United Kingdom. Pharmacoeconomics 1994;6:142-8.
28. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
29. Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster: Is the evidence spotty? J Infect Dis 1998;178(Suppl 1):S85-90.
30. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763-70.
31. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. J Eur Acad Dermatol Venereol 2000;14:23-33.
32. McKendrick MW, Care CC, Kudesia G, Oxley K, Eley AR. Varicella-zoster virus reactivation as a cause of patients presenting with unilateral pain? A prospective study [abstract P-23] In: Abstracts of the Third International Conference on the Varicella-Zoster Virus (Palm Beach Gardens, FL). New York: VZV Research Foundation, 1997.
33. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-5.
34. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998;178(Suppl 1):S71-5.
35. Whitley RJ, Weiss HL, Soong SJ. Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999;179:9-15.
36. Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovin, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998;178(Suppl 1):S76-80.
37. Wood MJ, Kroon S, eds. Management strategies in herpes: reducing the burden of zoster-associated pain-update. Worthing, UK: PAREXEL MMS Europe, 1996.
38. Johnson RW, Mandal BK. Guidelines for the management of shingles. Report of a working group of the British Society for the Study of Infection (BSSI). J Infect 1995;30:193-200.
39. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Famciclovir Herpes Zoster Clinical Study Group. Int J Antimicrob Agents 1994;4:241-6.
40. Tyring SK, Beutner KR, Bruce A, Tucker A, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster. Randomized, controlled trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9:863-9.
41. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days of 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
42. Whitley RJ, Weiss H, Gnann JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:376-83.
43. Higa K, Hori K, Harasawa I, Hirata K, Dan K. High thoracic epidural block relieves acute herpetic pain involving the trigeminal and cervical regions: comparison with effects of stellate ganglion block. Reg Anesth Pain Med 1998;23:25-9.
44. Pasqualucci A, Pasqualucci V, Galla F, et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anaesthetic and methylprednisolone. Acta Anaesthesiol Scand 2000;44:910-8.
45. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000;87:121-9.
46. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000:39.
47. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol 1994;35(Suppl):S50-3.
48. Watson CPN, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomised trial. Neurology 1998;51:1166-71.
49. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L for the Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia. JAMA 1998;280:1837-42.
50. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
51. Rice ASC, Maton S, Postherpetic Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
52. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000;20:280-5.
53. Rowbotham MC, Reisner-Keller L, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-8.
54. Rowbotham MC, Davies PS, Verkempinck C. Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
55. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrolment study. Pain 1999;80:533-8.
56. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
57. Kotani N, Kushikata T, Hashimoto H. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000;343:1514-9.
58. Loeser J. Surgery for postherpetic neuralgia. In: Watson CPN, ed. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier, 1993:221-37.
59. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45(Suppl 8):S41-6.
60. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
61. Attal N. Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 1999;173:12-24.
62. Pilowsky I. Psychological aspects of post-herpetic neuralgia: some clinical observations. Br J Med Psycbol 1977;50:283-8.
63. Ahn HJ, Lim HK, Lee YB, et al. The effects of famciclovir and epidural block in the treatment of herpes zoster. J Dermatol 2001:28:208-16.
64. Hwang SM, Kang YC, Lee YB, Yoon KB, Ahn SK, Choi EH. The effects of epidural blockade on the acute pain in herpes zoster. Arch Dermatol 1999;135:1359-64.